PUBLISHER: Grand View Research | PRODUCT CODE: 1750865
PUBLISHER: Grand View Research | PRODUCT CODE: 1750865
The global CRISPR-based diagnostics market size is expected to reach USD 7.55 billion by 2030, registering a CAGR of 16.57% from 2025 to 2030, according to a new report by Grand View Research, Inc. Technological innovations have been pivotal in propelling the CRISPR diagnostics market forward. The development of novel Cas enzymes, such as Cas12 and Cas13, has enhanced the sensitivity and specificity of CRISPR-based diagnostic tests. These advancements have facilitated the creation of rapid, point-of-care (POC) diagnostic tools capable of detecting pathogens and genetic mutations with high accuracy. In August 2023, Indian biotech startup CrisprBits collaborated with Molbio Diagnostics to develop CRISPR-based POC tests. This partnership led to the creation of the PathCrisp platform, designed for rapid and precise disease detection, and has been instrumental in expanding the availability of CRISPR diagnostics in resource-limited settings. Such collaborations exemplify how technological advancements are translating into practical diagnostic solutions.
The surge in market size is attributed to factors such as increased healthcare spending, heightened demand for gene editing technologies, and a growing prevalence of chronic and genetic diseases. For instance, the World Health Organization reported in 2024 that tuberculosis (TB) remained the second most common infectious disease worldwide, with an estimated 10.8 million people diagnosed in 2023 Such statistics underscore the pressing need for advanced diagnostic tools such as CRISPR-based tests.
The increasing incidence of genetic disorders and infectious diseases globally has amplified the demand for advanced diagnostic tools. According to the International Agency for Research on Cancer, the number of new cancer cases worldwide is expected to rise from 21.3 million in 2025 to 35.3 million by 2050. Similarly, research published in The Lancet in August 2024 highlighted a higher-than-expected prevalence of cystic fibrosis in non-European populations, particularly in the Indian subcontinent. These trends underscore the necessity for precise and rapid diagnostic methods, such as CRISPR-based tests, which can facilitate early detection and treatment of various diseases. The ability of CRISPR diagnostics to accurately identify specific genetic sequences makes them invaluable in managing the growing burden of genetic and infectious diseases.
Geographically, the CRISPR diagnostics market exhibits varying growth patterns. Asia Pacific currently holds the largest market share, driven by a high prevalence of infectious diseases and increasing investments in healthcare infrastructure. Conversely, North America is projected to be the fastest-growing region, attributed to substantial research and development investments and early adoption of advanced diagnostic technologies. For instance, in September 2023, Sherlock Biosciences received additional funding from the Bill & Melinda Gates Foundation to enhance the development of rapid, instrument-free molecular diagnostics leveraging CRISPR technology for Human Papillomavirus (HPV) detection . Such initiatives reflect the regional efforts to harness CRISPR technology in addressing public health challenges.